Athersys, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 04:40 pm EST
Share
Athersys, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 0.065 million compared to USD 4.79 million a year ago. Net loss was USD 13.67 million compared to USD 16.18 million a year ago. Basic loss per share from continuing operations was USD 1.15 compared to USD 1.76 a year ago.
For the nine months, revenue was USD 5.29 million compared to USD 4.79 million a year ago. Net loss was USD 59.53 million compared to USD 65.24 million a year ago. Basic loss per share from continuing operations was USD 5.58 compared to USD 7.41 a year ago.
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).
ATHERSYS, INC. 
